Trial Search Results

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

CareDx

Stanford Investigator(s):

Eligibility


Inclusion Criteria

   1. Any heart transplant recipient eligible for initiation and participation in the
   Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.

   2. Patients can be enrolled any time as long as they have not had more than 1 prior
   AlloMap.

   3. Written informed consent must be obtained prior to study enrollment. Exclusion
   Criteria

1. Pregnant Women.

Ages Eligible for Study

15 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Helen Luikart
650-724-2883
Not Recruiting